Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
:BIOA
BIOA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.88 - $26.62
Previous CloseN/A
Volume146.35K
Average Volume (3M)103.61K
Market Cap
$159.89M
Enterprise Value-$140.49M
Total Cash (Recent Filing)$297.30M
Total Debt (Recent Filing)$8.75M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 06, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding35,850,037
10 Day Avg. Volume94,540
30 Day Avg. Volume103,612
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.88
Enterprise Value/Revenue-36.37
Enterprise Value/Gross Profit-36.92
Enterprise Value/Ebitda1.72
Forecast
1Y Price Target
$5.00Price Target Upside12.11% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial clinical data for BGE-102 is on track, with plans to initiate a Ph1 study and provide single ascending dose data, which is crucial for informing future dose selections.
Drug DiscoveryThe company has expanded its drug discovery capabilities with exclusive access to the HUNT Biobank in Norway.
Financial PositionBioAge Labs has a strong cash position, with $313.4M in cash and equivalents, expected to support operations through 2029.
Bears Say
Earnings PerformanceBioAge reported a net loss of $21.6 million for the second quarter, resulting in a loss of $0.60 per share, which was greater than the estimate of a net loss of $15.0 million, or a loss of $0.41 per share.
Operating ExpensesThe difference between the estimate and the reported operating results was primarily driven by higher-than-expected operating expenses.
Pipeline UncertaintyOverall, caution remains as the APJ agonist pipeline resets, given prior challenges.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $2.88 and its highest was $26.62 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $159.89M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 82 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.482 by -$0.118.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.58.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 35,850,037 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.482. Following the earnings report the stock price went down -0.231%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
BioAge Labs, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$5.00 (12.11% Upside)
$5.00 (12.11% Upside)
Hedge Fund Trend
Decreased
By 314.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-35.88%
Trailing 12-Months
Asset Growth
95.95%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
BIOA Stock 12 Month Forecast
Average Price Target
$5.00
▲(12.11% Upside)
Technical Analysis
Ownership Overview
13.57% Insiders
2.81% Mutual Funds
49.32% Other Institutional Investors
27.20% Public Companies and
Individual Investors